pause_circle_filledNot Yet Recruiting

Venous thromboembolism, Children under 2 years

Bayer Identifier:

22195

ClinicalTrials.gov Identifier:

NCT05900388

EudraCT Number:

Not Available

EU CT Number:

Not Available
A study to observe the pattern of use and safety of rivaroxaban in children under 2 years old with venous thromboembolism (VTE)

Trial purpose

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).

VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.

Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.

The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.

The main information that researchers will collect in this study:
•   Age, gender, and other information about the child and their illness
•   Type of VTE treatment given to the child
•   Occurrence of medically important bleeding and its severity

Further information that researchers will collect:
•   Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE
•   Return of VTE symptoms
•   Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals)
Besides this data collection, no further tests or examinations are needed in this study.

The data for this study will be collected from electronic health records and health insurance claims data until 2026.

Researchers will observe each child during treatment until:
•   end of the anticoagulation treatment period e.g. discontinuation of all study drugs,
•   their information is no longer available, or
•   the study ends.

Key Participants Requirements

Sex

All

Age

NaN - 2 Years
  • - Evidence of initiation of an anticoagulant therapy (index drug), either rivaroxaban oral suspension or other anticoagulation therapies (heparins, Vitamin K antagonists (VKAs), other Direct oral anticoagulants (DOACs)). Initiation will be defined as a first record of any anticoagulation therapy (rivaroxaban or SOC) without any anticoagulation therapy in the previous 6 months, or since date of birth for children less than 6 months
    - Evidence of a prior VTE diagnosis (index VTE), defined as the presence of at least one primary/main or secondary diagnosis code for VTE recorded in inpatient setting in the previous 30 days
    - Age less than two years on index date.
    - Baseline period for availability of patient data history in the data source. A minimal baseline period of six months before index date for children aged between six months and two years, and a baseline period since birth for children less than six months of age will be required.
  • - None

Trial summary

Enrollment Goal
850
Trial Dates
December 2025 - June 2029
Phase
Phase 4
Could I Receive a placebo
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Not yet recruiting
Many locationsMany locations, France
Not yet recruiting
Many locationsMany locations, Sweden
Not yet recruiting
Many locationsMany locations, Denmark
Not yet recruiting
Many locationsMany locations, Spain

Primary Outcome

  • Descriptive summary of demographic characteristics of patients
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2026
  • Descriptive summary of characteristics of index venous thromboembolism (VTE)
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2026
  • Co-morbidities reported in the previous six months before index date, or since date of birth for children less than six months
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2026
  • Prior treatments reported in the previous six months before index date (or since date of birth for children less than six months)
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2026
  • Comedication during follow-up
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Descriptive summary of Health resource utilization in the previous six months before index date (or since date of birth for children less than six months)
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2026
  • Duration of oral, nasogastric/gastric feeding before index date, if available
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2026
  • Substance and class of anticoagulant drug therapy
    For analyzing Index drug therapy and Maintenance therapy.
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Duration of use anticoagulant drug therapy
    For analyzing Index drug therapy and Maintenance therapy.
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Dosing of anticoagulant drug administration
    For analyzing Index drug therapy and Maintenance therapy.
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Route of anticoagulant drug administration
    For analyzing Index drug therapy and Maintenance therapy.
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Switching to other anticoagulant therapy (Yes/No)
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Number of successive anticoagulation agents during an anticoagulant treatment period
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Sequence of successive anticoagulation agents during an anticoagulant treatment period
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Incidence and severity of major bleeding according to anticoagulation therapy
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Incidence and severity of clinically Relevant Non-Major (CRNM) bleeding according to anticoagulation therapy
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027

Secondary Outcome

  • Time trends by calendar year in patient characteristics
    Description by calendar year of age group at index date and medical history at index date.
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2026
  • Time trends by calendar year in anticoagulation treatment patterns
    Description by calendar year of class of anticoagulation therapy at initiation.
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2026
  • Incidence of recurrent symptomatic VTE according to anticoagulation therapy
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027
  • Physician specialty and care settings (inpatient care, secondary outpatient care, primary care) for prescriptions of anticoagulation therapy
    date_rangeTime Frame:
    Retrospective data analysis from 2021 to 2027

Trial design

Xarelto Paediatric VTE PASS Drug Utilization Study: An observational, longitudinal, multi-source drug utilization safety study to evaluate the drug use patterns and safety of rivaroxaban oral suspension in children under two years with venous thromboembolism
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here for access to information about Bayer’s transparency standards and Bayer studies.